Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767736 | 0.83 | MAPT (0.47) | L3MBTL1LMNANQO1MEN1KMT2A | |
| SCHEMBL28452086 | 0.82 | NQO1 (0.39) | L3MBTL1LMNANQO1MEN1KMT2A | |
| SCHEMBL19867565 | 0.80 | NQO1 (0.37) | L3MBTL1NQO1MEN1KMT2ATDP1 | |
| SCHEMBL19867567 | 0.79 | LMNA (0.50) | L3MBTL1LMNANQO1MEN1KMT2A | |
| SCHEMBL21611185 | 0.79 | CYP3A4 (0.37) | MEN1KMT2ATDP1TSHRKDM4E | |
| SCHEMBL9114461 | 0.76 | NQO1 (0.64) | L3MBTL1LMNANQO1MEN1KMT2A | |
| SCHEMBL19867421 | 0.76 | TP53 (0.43) | L3MBTL1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19334270 | 0.74 | SLC6A2 (0.33) | FFAR1 | |
| SCHEMBL19867463 | 0.74 | P4HB (0.43) | L3MBTL1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19867461 | 0.73 | MEN1 (0.41) | L3MBTL1LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439901-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9439902-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308204-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-8669380-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2496583-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065512-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | L3MBTL1 3622/4885LMNA 4031/4885NQO1 2731/4885 |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | L3MBTL1 3622/4885LMNA 4031/4885NQO1 2731/4885 |
| US-20130225487-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | L3MBTL1 3622/4885LMNA 4031/4885NQO1 2731/4885 |
| US-20150065513-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | L3MBTL1 3622/4885LMNA 4031/4885NQO1 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.